| 51.18 Data as of Jun 06 |  +0.58 / +1.15%Today’s Change | 41.68 Today|||52-Week Range 54.00 | +17.74% Year-to-Date |
| Impax Reduces Workforce - Analyst Blog Jun 06 / Zacks.com | Glaxo/Renaissance Ink Deal - Analyst Blog Jun 04 / Zacks.com |
| Sarissa's Stake in VIVUS Points to Renewed Interest in the Company Jun 06 / MotleyFool.com | 'Mad Money' Lightning Round: I'm Buying Under Armour Jun 04 / TheStreet.com |
| Pfizer's Big Chance Jun 06 / MotleyFool.com | Glaxo Reports Votrient Data - Analyst Blog Jun 03 / Zacks.com |
| As If Amarin Needs Another Worry, Here Comes A Vascepa FDA Panel Jun 06 / TheStreet.com | GSK/Genmab Report Positive Arzerra Data - Analyst Blog May 31 / Zacks.com |
| How AstraZeneca Measures Up as a GARP Investment Jun 05 / MotleyFool.com | Array/ONTY to Co-develop ARRY-380 - Analyst Blog May 31 / Zacks.com |
| Previous close | 50.60 |
| Today’s open | 51.34 |
| Day’s range | -- - -- |
| Volume | 4,491,297 |
| Average volume (3 months) | 2,864,601 |
| Market cap | $124.6B |
| Dividend yield | 4.58% |
| Earnings growth (last year) | -12.13% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +8.14% |
| Revenue growth (last year) | -4.52% |
| P/E ratio | -- |
| Price/Sales | 2.54 |
| Price/Book | 13.49 |
| Today’s change | Today’s % change | |
|---|---|---|
| SNYSanofi SA | +0.36 | +0.68% |
| MRKMerck & Co Inc | -0.13 | -0.27% |
| NVSNovartis AG | +0.39 | +0.55% |
| BMYBristol-Myers Squibb... | +0.83 | +1.80% |
| Next reporting date | July 24, 2013 |
| EPS forecast (this quarter) | $0.83 |
| Annual revenue (last year) | $42.1B |
| Annual profit (last year) | $7.3B |
| Net profit margin | 17.27% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Andrew Philip Witty |
Chief Financial Officer & Executive Director Simon Dingemans |
Corporate headquarters Brentford, Greater London |
.
